Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

606
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
606
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.7K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.7K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

982
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
982
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.7K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.7K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.4K
The pathophysiology of pneumonia involves the following steps:
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individually Tailored Physiotherapy in Persons With Respiratory Symptoms Related to Post-Acute Sequelae of COVID-19: A Feasibility Study With Mixed Methods.

Health science reports·2025
Same author

The effect of COVID-19 and sex differences on natural killer cell cytotoxicity.

Frontiers in cellular and infection microbiology·2025
Same author

Persistent NK cell deficiency associated with pulmonary cryptococcosis.

Annals of clinical microbiology and antimicrobials·2025
Same author

The pore-forming apolipoprotein APOL7C drives phagosomal rupture and antigen cross-presentation by dendritic cells.

Science immunology·2024
Same author

Combined medical-interventional approaches for the management of complex fungal balls: a case series as a viable alternative in non-surgical patients.

Therapeutic advances in respiratory disease·2024
Same author

"I Had to Know About It, I Had to Find It, I Had to Know How to Access it": Experiences of Access to Rehabilitation Services Among People Living with Long COVID.

Physiotherapy Canada. Physiotherapie Canada·2024
Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026
Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026
Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026
Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026
Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans
11:07

Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans

Published on: December 19, 2014

13.1K

Cryptococcal Lung Infections.

Kate Skolnik1, Shaunna Huston2, Christopher H Mody3

  • 1Division of Respirology, Department of Internal Medicine, Rockyview General Hospital, University of Calgary, Respirology Offices, 7007 14th Street Southwest, Calgary, Alberta T2V 1P9, Canada.

Clinics in Chest Medicine
|August 12, 2017
PubMed
Summary
This summary is machine-generated.

Cryptococcus is a major fungal pathogen causing severe infections, especially in individuals with HIV/AIDS. Standard treatment for severe pulmonary cryptococcosis involves Amphotericin B, flucytosine, and fluconazole.

Keywords:
CryptococcosisCryptococcusEndemic mycosesFungal lung infectionTreatment

More Related Videos

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

940
Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways
10:06

Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways

Published on: December 13, 2024

920

Related Experiment Videos

Last Updated: Feb 24, 2026

Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans
11:07

Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans

Published on: December 19, 2014

13.1K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

940
Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways
10:06

Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways

Published on: December 13, 2024

920

Area of Science:

  • Mycology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Cryptococcus is a globally prevalent invasive fungal pathogen.
  • It is a leading cause of death in patients with acquired immunodeficiency virus (HIV).
  • Cryptococcus neoformans and Cryptococcus gattii are the primary species causing human disease.

Purpose of the Study:

  • To summarize the clinical relevance of Cryptococcus species.
  • To outline the spectrum of pulmonary manifestations.
  • To describe current treatment strategies for cryptococcal infections.

Main Methods:

  • Literature review of Cryptococcus epidemiology and clinical management.
  • Analysis of treatment guidelines for severe pulmonary and disseminated disease.

Main Results:

  • Pulmonary cryptococcosis presents with variable severity, from mild symptoms to life-threatening conditions.
  • Treatment decisions depend on infection severity, dissemination, and host immune status.
  • Standard therapy for severe infections includes Amphotericin B and flucytosine, followed by fluconazole.

Conclusions:

  • Cryptococcal infections, particularly in immunocompromised individuals, require prompt and tailored treatment.
  • Effective management relies on understanding disease spectrum and utilizing established antifungal regimens.
  • Continued research is needed to optimize outcomes for patients with cryptococcosis.